CJIMI998;4(4):259- 262 9 259 9 Clinical Study on Effect of Fuzheng Kangbai Granule on Long-Term Survival of Patients with Acute Leukemia Ma Rou (~l~ ~i~), Liu Feng (~] ~[!), Yang Jingmin ($.~5~ff1~), Ma Ling.(~ ~) Xu Yonggang ( i , ~ ) , Hu Naiping (i~)-~5]z), Hu Xiaomei (i~li~l~j~) Xue Xiangjun ( ~ N g ) , Li Liu (~i t~lI), Wang Nan (2E ~) Department of Hematology, Xiyuan Hospital, China Academy of TCM, Beijing (100091) ABSTRACT Objective: To observe the effect of Fuzheng Kangbai Granule (FZKBG) on long-term survival of patients with acute leukemia, and to study its mechanism in treating minimal residual leukemia. Methods: FZKBG was used to treat 90 cases of completely remitted acute leukemiato observe the effect of treatment on 5- year event free interval (EFI), over survival (OS) and the immune function of patients. Results: Five-year EFI and OS of the 90 cases were 62.4 % and 77.2 % respectively, and the immune functions after FZKBG therapy were improvedsignificantly. Conclusion: FZKBG could increase the 5-year EFI and 5-year OS, which might be reached through improving immune function of patients. KEY WORDS Fuzhen Kangbai Granule, acute leukemia, quality of life span, immunefunction At the present time, chemotherapy is the chief treatment of acute leukemia (AL). But while chemotherapy eliminates pal~hogens, it also damage the organism itself. And there- fore, when AL has gotten complete remission by chemotherapy and entered into minimal residual leukemia (MRL) state, the patients would, inevitably, suffer from Deficiency, showing the characteristics of "body impair- ment after Evil pathogen removed" and "both Deficiency of Qi and Yin Syndrome ''(1) . The authors expected to rebuild and restore the im- mune function, and to prevent the recurrence and prolong the leukemia-free survival (LFS) of MRL patients by way of supporting healthy energy. This article reported the clinical study on effect of Fuzheng Kangbai Granule (FZK- BG) on long-term survival of AL patients. METHODS Clinical Materials The study included 90 in-patients who had achieved complete remission (CR) from July 1st, 1992 to June 30, 1997 in the au- thors' or other hospitals. They were 56 males and 34 females, aged 13 - 59 years, and their CR period was 0.5 - 7.5 months. Among them 81 suffered from acute non-lymphocytic leukemia (5 from M1, 8 from M2, 66 from Ma, 1 from Ma and 1 from MT), and 9 from acute lymphocytic leukemia (all Lz). The di- agnosis and therapeutic effect were evaluated according to the standard published by Zhang Zhinan (2) . Method of Treatment For the Ma cases, 0.01% As203 injection (1.0 mg/ml) 10 ml was added in 5% glucose solution for intravenous drip per day and given for 14 days as one therapeutic course for 6 course. To other acute non-lymphocytic leukemia patients, DA (DNR + Ara-C) or NA ( NVT + Ara-C) scheme was used for at least 6 courses. And for acute lymphocytic leukemia cases, VDLP, VDAP, HD-MTX were applied alternately for at least 6 courses. Among them 2 patients received auto-bone marrow trans- plantation. All patients took FZKBG 12 g, 3 times a day for 3 months successively as one course, 2 - 12 courses were received in gener- al. FZKBG consisted of Radix Ginseng, Radix Astragalus, Radix Polygoni Multiflori, Herba Epimedium, Radix Asparagus, Fructus Psoralea, Fructus Ligustrum Lucidum and Rhizoma Atractylodes Alba, containing 82.5 g of crude drugs in 12 g of preparation, which was supplied by the pharmaceutical factory of the authors' hospital.